Liminal BioSciences Inc (LMNL) 시세

Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP

Liminal Biosciences’ stock soars 91% after getting takeover offer that’s more than double its price
Published: April 5, 2023 at 8:08 a.m. ET
By Ciara Linnane
comments
Email icon
Facebook icon
Twitter icon
Linkedin icon
Flipboard icon
Print icon
Resize icon
Referenced Symbols

LMNL
-4.23%
Liminal Biosciences Inc.’s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it’s received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest. The stock closed Tuesday at $3.62. Liminal specializes in discovering and developing novel and distinctive small molecule therapeutics to treat metabolic, inflammatory and fibrotic diseases. The board will review the offer and has formed a special committee of independent directors.


Advertisement
Read full story
Read Next
Barron's: Gold Prices Are Near

I was very tempted to try another swing on this one. Passing it up. Beyond even my own risk level. Made a very nice swing here back in January. Haven't touched it since.

Good luck if you're taking this one on.

LMNL daily


We'll see if I shoulda coulda latter.

LMNL 1.97 marked.

This junk keeps going down??

Close over 4?

Yeah pretty big news here. Could see a good spike

Big news!

Say goodbye.... Never buy this scam

Time to buy

yes it will open at 3.00

Any idea whats the opening price would be and where we headed????

Should get interesting over here.....

Not this stuck!

Zim.....wasssupppp????

Double more then normal volume...buying

Volume today.....

Look what I saw over on Stockhouse, seems serious.

1 BILLION $$$$ lawsuit- Repost
Let's get the word out!! Keep this on top so investors know the scam and know that Justice WILL be served up!

Peter Thomson and his goons outright lied and deceived thousands of investors in order to steal this company! He has also denied children and families life saving treatments out of pure greed!!! These investors, now plaintiffs, knew this company intimately for 20 years, it had the potential for Billions and Thomson also knew that. He wanted it for his family at the expense of many. Do you think he will cut off his right arm and now pay plaintiffs for what he stole to save his reputation, or throw his goons under the bus and still pay? Either way this publicly traded company is in their final chapter thanks to his unethical business practises.

We are going to publicly expose him and his companies for what they did! This isn’t the first time they’ve done this; they’ve targeted Prometic years ago and systematically attacked it! We’re only going to get louder. Justice must stand up to protect our markets from these predators for all investors who trade on publically traded exchanges and make an example out of Thomson and his goons! These a-holes certainly have what's coming to them!

Stickyscamo even if you could wrap his little head around this, you are part of this international scam whether you know it or not, playing ignorant with your irrelevant cheerleading is no excuse! There's no chance in H any judge would not see what they did to us; they ruined lives out of pure greed! It's plain to see, we got these white collar scum just where we want them! You think the team is working at Liminal? Not a chance dude they are focused on this, it will be crippling for them! Geez, you don’t even care that they hid this lawsuit from the current round of suckers for weeks. But hey, by all means keep giving them your money, buy into the manipulation while the fat rats leave the ship!

Stickyscamo! you mindless tool, I certainly hope that you’ve invested all of your savings in here. I don’t know from which rock you crawled out from under, but attempting to sucker others in here for Peter Thomson, or to increase your portfolio is extremely low of you!

We have got our thumb on these predators now, this train ain’t a stopping! This I guarantee!!
The markets need to become fully aware of the injustice here, heck a movie should be made! Brad Pitt could play Peter Thomson!

I told you all this was a great position to be in.

See I told you, tomorrow will be better!

This is getting ready to explode. Get ready for $54/share.

It’s quiet before the storm.

* * $LMNL Video Chart 12-21-2020 * *

Link to Video - click here to watch the technical chart video

1 year anniversary of 1st spike to 19.49, big volume will send this.

This will boom soon. News and very tight float is gonna get vertical.

News will drop any day now with data. Perfect time to have been loading at these discounted levels here. ASH conf this weekend with presentations

https://www.hematology.org/meetings/annual-meeting

Waiting on volume. Very tight trading, turn up the volume!!!!

And today is not, lol.

Today is the day!!!

This is getting cheap deep diving anyone

Intraday cup and handle coming

$LMNL sweet biotech runner https://finance.yahoo.com/news/liminal-biosciences-commences-collection-convalescent-213100194.html

This has a gap to fill at 117-120. Load up.

Dam I missed this one !!! Geez !! Great day

PFSCF: effective Oct. 7,2019 Prometic Life Sciences Inc. will change to Liminal Biosciences Inc.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

News - Prometic Shareholders Approve Name Change to Liminal BioSciences Inc.
Canada NewsWire

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 3, 2019

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 3, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced results from the special meeting of shareholders held in Montreal, Quebec, on October 3, 2019. Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences Inc.

"We appreciate the continued support of our shareholders as we make progress on our focused strategy to build shareholder value and transition to a new vision and values reflective of our new name, Liminal BioSciences," stated Kenneth Galbraith, Chief Executive Officer of the Company.

The effective date of the change of name will be the date of issuance of a certificate of amendment under the Canada Business Corporations Act, which we expect to receive shortly. The Company's new website at www.liminalbiosciences.com will be launched concurrently.

The Toronto Stock Exchange ("TSX") has accepted notice of the proposed change of name and the Company's common shares on the TSX are expected to begin trading under the symbol "LMNL" on or about Monday, October 7, 2019, subject to TSX final approval.

As a result of the name change, the Company's CUSIP number for its common shares will be changed to 53272L103 and its ISIN to CA53272L1031.

About Prometic

Prometic (www.prometic.com) is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. Prometic's research involves the study of several G-protein-coupled-receptors, GPR40 and GPR120, known as free fatty acid receptors (FFAR's) and a related metabolic receptor, GPR84. These drug candidates have a novel mechanism of action as agonists ("stimulators") of GPR40 and GPR 120, and antagonists ("inhibitors") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alström Syndrome after further consultation and approval by the FDA and EMA. A second drug candidate, PBI-4547, is currently in a Phase 1 clinical study.

Prometic also has leveraged its lengthy experience in bioseparation technologies to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived therapeutic product is RyplazimTM (plasminogen) for which the Company expects to file a BLA with the US FDA in the first half of 2020 seeking approval to treat patients with congenital plasminogen deficiency. The Company also operates a contract development and manufacturing operation in the United Kingdom, deriving revenue through sales of affinity chromatography media.

Prometic has active business operations in Canada, the United States, Isle of Man and the United Kingdom.

Forward Looking Statements

This presentation contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in the Annual Information Form for the year ended December 31, 2018, under the heading "Risks and Uncertainties related to Prometic's Business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

SOURCE ProMetic Life Sciences Inc.

PFSCF one for 1,000 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Why the sudden jump in price?

----------------------------------------------------------------------------------------------------------------------------------------------------------------------

All comments are my personal perspective only and should not be considered investment advice. Be a responsible investor and do your own
due diligence (i.e. research) before considering information from anyone in a public forum.

“It’s amazing how much panic one honest man can spread among a multitude of hypocrites.” American economist Dr. Thomas Sowell

Notice: This is NOT a compensated post.

More bad news.

Why is this falling?

Stock is showing a sign of good things to come....

buyers everywhere!

$2.00 approaching

Dr. Soon-Shiong pulls trigger to purchase 44,000,000 shares of PFSCF.
Commercializations plasminogen expected in 2017


California Capital Equity, LLC acquires 44 million ProMetic shares through the exercise of all outstanding warrants

PR Newswire PR NewswireFebruary 6, 2017
LAVAL, QC, Feb. 6, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF) ("ProMetic" or the "Corporation") announced today that California Capital Equity, LLC, has exercised 44,791,488 share purchase warrants at a price of $0.47 per share for total proceeds of $21,051,999.36 to the Corporation.
"Our increased equity position in ProMetic represents a long term and strategic investment for us", said Dr. Patrick Soon-Shiong, Chief Executive Officer of California Capital Equity, LLC. "ProMetic has robust proprietary therapeutic platforms, promising growth potential and several plasma derived therapeutics expected to reach commercialization stages, starting in 2017 with plasminogen. We, through other investment vehicles, also have an on-going partnership with ProMetic in relation to IVIG and anticipate further collaborations going forward", added Dr. Soon-Shiong.

Positive results:
http://finance.yahoo.com/news/prometics-plasminogen-drug-successfully-used-113000811.html?.tsrc=applewf

Clinical trials approved in UK for leading drug candidate.
Phase II underway in CANADA
http://finance.yahoo.com/news/prometics-pbi-4050-cleared-commence-103000743.html?.tsrc=applewf

Picking-up 1.39

Starting a reload on this little sleeper.
§PFSCF

Go to stockhouse.com for more accurate info on PLI.t

Hello Guys, I'm new here.

Recently I read an interview with Pierre Laurin and Michel Carignan(CEO Prometic Life Canada and /The Swing Trading Show) about a fibrinogen deal, which is expected in the first half of this year?I remember it well because I was overwhelmed.
Could any board member confirm this for me or indicate that it is still current? If this is right, this could any time.
And is it likely that share will rise?

Thanks for your help

Multi_Bagger

http://article.wn.com/view/2015/04/14/ProMetic_Announces_50_Million_Bought_Deal_Offering_to_Fund_S/

My prediction is more reasonnable... 5$ at the end of 2015

I'm predicting over $15.00 in a year and a half.. Imho

This here is the real deal

§ PFSCF 2.18 §
Just keep on adding!!!
§PFSCF